clinical trials

Recent Rosacea Blog Posts

A clinical trial at Stanford Dermatology is seeking trialists to join a study looking at Secukinumab as a treatment for the papules and pustules, and redness associated with rosacea. If you are interested, and meet the requirements for the trial, please contact them via their details below. What is Secukinumab? Secukinumab (brand name Cosentyx) has recently become […]

Continue Reading

If you live in the San Diego area and qualify you may be interested in the following clinical trial that is recruiting participants. A Rosacea study is for a topical minocycline foam and qualifying criteria are as follows: > 18 years of age male and females Moderate to severe rosacea (15-75 facial papules and pustules […]

Continue Reading

Galderma is set to trial the usage of Soolantra and Oracea in combination to treat sufferers of severe rosacea. What is Severe Rosacea? Severe rosacea is taken here to be participants with at least 20 but not more than 70 papules and pustules. The trial will aim to show that the addition of Oracea to […]

Continue Reading

Accuitis to trial ACU-D1 for Rosacea

A drug that is said to inhibit nuclear factor kappa beta (NFkB), is to be trialed as a rosacea treatment. The new treatment, code named ACU-D1 will be tested as a treatment primarily for the papules and pustules of rosacea. Clinical Trial NCT03064438 Efficacy of Accu-D1 in the Treatment of Acne Rosacea The study evaluates the safety, […]

Continue Reading

Dermata DMT 210 works for redness and bumps of rosacea

A press release today highlighting a new drug, based on Arazine, that is claimed to help both the redness and papules and pustules of rosacea through its ability to down regulate G-protein coupled receptor (GPCR) signaling. The company developing DMT 210, Dermata, is releasing results from their phase 1 trials, and are looking to commence phase 2 trials […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.